Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats.

Olivier Le Bacquer,Christophe Montaurier,Vincenzo Di Marzo,Jérôme Salles,Stéphane Walrand,Fabiana Piscitelli,Phelipe Sanchez,Vincent Martin

doi:10.1002/jcsm.12855

Abstract

BackgroundActivation of the endocannabinoid system (ECS) is associated with the development of obesity and insulin resistance, and with perturbed skeletal muscle development. Age‐related sarcopenia is a progressive and generalized skeletal muscle disorder involving an accelerated loss of muscle mass and function, with changes in skeletal muscle protein homeostasis due to lipid accumulation and anabolic resistance. Hence, both obesity and sarcopenia share a common set of pathophysiological alterations leading to skeletal muscle impairment. The aim of this study was to characterize how sarcopenia impacts the ECS and if these modifications were related to the loss of muscle mass and function associated with aging in rats.MethodsSix‐month‐old and 24‐month‐old male rats were used to measure the contractile properties of the plantarflexors (isometric torque–frequency relationship & concentric power–velocity relationship) and to evaluate locomotor activity, motor coordination, and voluntary gait by open field, rotarod, and catwalk tests, respectively. Levels of endocannabinoids (AEA & 2‐AG) and endocannabinoid‐like molecules (OEA & PEA) were measured by LCF‐MS/MS in plasma, skeletal muscle, and adipose tissue, while the expression of genes coding for the ECS were investigated by quantitative reverse transcription PCR (RT‐qPCR).ResultsSarcopenia in old rats was exemplified by a 49% decrease in hindlimb muscle mass (P < 0.01), which was associated with severe impairment of isometric torque, power, voluntary locomotor activity, motor coordination, and gait quality. Sarcopenia was associated with (1) increased 2‐AG (+32%, P = 0.07) and reduced PEA and OEA levels in the plasma (−25% and −40%, respectively, P < 0.01); (2) an increased content of AEA, PEA, and OEA in subcutaneous adipose tissue (P < 0.01); and (3) a four‐fold increase of 2‐AG content in the soleus (P < 0.01) and a reduced OEA content in EDL (−80%, P < 0.01). These alterations were associated with profound modifications in the expression of the ECS genes in the adipose tissue and skeletal muscle.ConclusionsTaken together, these findings demonstrate that circulating and peripheral tissue endocannabinoid tone are altered in sarcopenia. They also demonstrate that OEA plasma levels are associated with skeletal muscle function and loss of locomotor activity in rats, suggesting OEA could be used as a circulating biomarker for sarcopenia.

Highlights

Age-related sarcopenia is a progressive and generalized skeletal muscle disorder involving an accelerated loss of muscle mass and function without any underlying disease
The aim of the present study was (1) to characterize the changes of the circulating and tissue levels of endocannabinoids in a context of sarcopenia, (2) to characterize the alterations of the endocannabinoid system (ECS) genes in the adipose tissue and skeletal muscle, and (3) to analyse whether these alterations can be associated with muscle mass, function, and mobility in old rats
Because aging is associated with increased adiposity and loss of muscle mass, we measured body composition by EchoMRI and the mass of several hindlimb muscles of 6-month-old and 24-month-old rats

Summary

Introduction

Age-related sarcopenia is a progressive and generalized skeletal muscle disorder involving an accelerated loss of muscle mass and function without any underlying disease. Several molecular mechanisms have been described as causes for sarcopenia that refer to very different levels of muscle physiology These mechanisms cover quantitative and qualitative changes in skeletal muscle structure, decreased contractility capacity, impaired control of muscle contraction by the nervous system, impaired regenerative potential, and changes in the regulation of protein metabolism driven by nutrients and hormones. Age-related sarcopenia is a progressive and generalized skeletal muscle disorder involving an accelerated loss of muscle mass and function, with changes in skeletal muscle protein homeostasis due to lipid accumulation and anabolic resistance Both obesity and sarcopenia share a common set of pathophysiological alterations leading to skeletal muscle impairment. These alterations were associated with profound modifications in the expression of the ECS genes in the adipose tissue and skeletal muscle

Objectives

Methods

Results

Conclusion